Skip to main
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc is positioned for optimistic growth due to its innovative silent and replace-based therapeutics for Oculopharyngeal Muscular Dystrophy (OPMD), showing promising initial results that could lead to expedited regulatory interactions and potential accelerated approvals. The interim data from the increased patient cohort reflects a 100% responder rate, with sustained improvements in critical swallowing metrics, suggesting a significant therapeutic impact, which may enable premium pricing strategies. Additionally, long-term data indicates a trend of progressive improvement over time, enhancing the overall probability of obtaining market approval and reinforcing the company's strong growth potential in the biotechnology sector.

Bears say

Benitec Biopharma Inc. reported a net loss of $0.21 per share in F1Q26, which was better than the forecasted loss of $0.41 per share, primarily due to a higher-than-anticipated weighted average number of shares outstanding. However, the company faces significant risks, including potential delays or failures in obtaining regulatory approval for its flagship product BB-301, which could adversely affect the company’s stock price. Additionally, the ongoing clinical trial's slower-than-expected progress and the possibility of negative data or unexpected side effects further contribute to a negative outlook, compounded by concerns regarding long-term equity dilution.

BNTC has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 5 analysts, BNTC has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.